Sumanta K. Pal

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S6 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S5 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S4 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S3 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Table S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Table S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma

  Journal for ImmunoTherapy of Cancer · 2026-05-01

• Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma

  European Urology · 2026-04-01 · 1 citations

• Computational study on QSAR modeling, molecular docking, and ADMET profiling of pyrazole-modified catalpol derivatives as prospective dual inhibitors of VEGFR-2/BRAF V600E

  Journal of Computer-Aided Molecular Design · 2025-12-19 · 4 citations

• Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)

  Clinical Genitourinary Cancer · 2025-12-12 · 1 citations

• Supplementary table 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

  2025-11-25

• Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

  2025-11-25

• Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

  2025-11-25

• Supplementary table 2 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

  2025-11-25

• Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study

  ESMO Open · 2025-11-20 · 1 citations

• CNT as a robust delivery vehicle for anti-breast cancer drugs: A combined DFT and in-silico study

  Journal of Molecular Graphics and Modelling · 2025-11-18 · 3 citations

• 450 Outcomes of immune-checkpoint inhibitors rechallenge in metastatic clear cell renal cell carcinoma: results from a global real-world evidence study

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

  Cancers · 2025-10-09 · 1 citations